| 摘要 |
The present invention relates to a HIF-lalpha activator containing clioquinol and its derivatives as an active ingredient. Clioquinol and its derivatives of the invention inhibit HIF-1alpha(hypoxia-inducible factor-lalpha) ubiquitination in normoxic cells and thus accumulate HIF-lalpha. In the meantime, CQ inhibits FIH-I activity and thereby induces transcription activity of the accumulated HIF-lalpha, resulting in the induction of expressions of HIF-lalpha target genes VEGF (vascular endothelial growth factor) and EPO (erythropoietin). Therefore, clioquinol and its derivatives can be effectively used as a therapeutic agent for ischemic disease. |
